Absci

Founder-CEO Sean McClain remains at the helm and signed the March 24, 2026 10-K; management and aligned holders collectively owned over 44 percent as of March 6, 2026, which supports long-term orientation. Strategic partners add external validation (AstraZeneca milestone; AMD collaboration and equity investment).

However, the team’s track record in bringing assets through late-stage clinical development and commercialization remains to be established.